Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96PZ0
UPID:
PUS7_HUMAN
Alternative names:
-
Alternative UPACC:
Q96PZ0; Q75MG4; Q9NX19
Background:
Pseudouridylate synthase 7 homolog plays a pivotal role in RNA metabolism, catalyzing the pseudouridylation of various RNA types, including mRNAs, tRNAs, and snRNAs. This modification process is crucial for RNA stability and function, impacting protein synthesis, mRNA splicing, and translation initiation.
Therapeutic significance:
Linked to the disorder Intellectual developmental disorder with abnormal behavior, microcephaly, and short stature, understanding the role of Pseudouridylate synthase 7 homolog could open doors to potential therapeutic strategies.